董事介绍
注:董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Aditya Puri | 男 | Director | 46 | 8.21万美元 | 未持股 | 2017-04-28 |
| Mark S. Gold | 男 | Director | 67 | 6.48万美元 | 未持股 | 2017-04-28 |
| James F. Dempsey | 男 | Chief Scientific Officer and Director | 46 | 35.10万美元 | 未持股 | 2017-04-28 |
| Henry A. McKinnell | 男 | Director | 74 | 8.06万美元 | 未持股 | 2017-04-28 |
| Brian K. Roberts | 男 | Director | 46 | 6.13万美元 | 未持股 | 2017-04-28 |
| Theodore T. Wang | 男 | Director | 50 | 未披露 | 未持股 | 2017-04-28 |
| Caley Castelein | 男 | Director | 46 | 9.37万美元 | 未持股 | 2017-04-28 |
| Chris A. Raanes | 男 | President, Chief Executive Officer and Director | 52 | 62.25万美元 | 未持股 | 2017-04-28 |
| David Bonita | 男 | Director | 41 | 8.37万美元 | 未持股 | 2017-04-28 |
| Josh Bilenker | 男 | Director | 45 | 8.21万美元 | 未持股 | 2017-04-28 |
高管介绍
注:高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| James F. Dempsey | 男 | Chief Scientific Officer and Director | 46 | 35.10万美元 | 未持股 | 2017-04-28 |
| Douglas H. Keare | 男 | Chief Operating Officer | 52 | 未披露 | 未持股 | 2017-04-28 |
| Chris A. Raanes | 男 | President, Chief Executive Officer and Director | 52 | 62.25万美元 | 未持股 | 2017-04-28 |
| Ajay Bansal | 男 | Chief Financial Officer | 55 | 186.55万美元 | 未持股 | 2017-04-28 |
| Ajay Bansal | 男 | Chief Financial Officer | 55 | 未披露 | 未持股 | 2017-04-28 |
董事简历
中英对照 |  中文 |  英文- Aditya Puri
-
Aditya Puri,他担任我们的董事会成员(2015年2月以来)。他曾担任Xeraya Capital(负责Khazanah Nasional Berhad的生命科学投资)的投资主管(2012年10月以来)。此前,他曾担任Khazanah Nasional公司的生命科学部门(负责Khazanah公司的生命科学投资)的主管(2011年11月以来)。此前,他曾在大波士顿地区兼职咨询,涉及Harvard University、Massachusetts Institute of Technology(MIT)的各种附属各种医疗和清洁技术公司(2009年至2011年)。他也曾担任Salary.com的董事总经理,负责全球开发(从2007年7月到2008年4月)。他曾任职the Yankee Group(全球技术研究和咨询公司)(从2000年9月到2007年3月),最终担任副总裁兼领导团队成员。1997年3月至2000年4月,他曾任职Boston Scientific(财富500强医疗设备制造商)。他任职于一些投资和医疗领域的私人公司的董事会。他持有the University of Southern Maine的学士学位,以及the MIT Sloan School of Management的工商管理硕士学位。
Aditya Puri served as a member of our board of directors from March 2016 to his resignation in August 2020. Mr. Puri previously served on the board of directors of medical device companies ConforMIS Inc. and ViewRay, Inc. Since October 2012 Mr. Puri has served as an Investment Partner at Xeraya Capital, which, among other mandates, is the exclusive life sciences investments platform for Khazanah Nasional Berhad, the Malaysian government’s strategic investment fund. Mr. Puri received a B.S. from the University of Southern Maine, and an M.B.A from the MIT Sloan School of Management. He has also passed all parts of the U.S. Uniform CPA Examination. - Aditya Puri,他担任我们的董事会成员(2015年2月以来)。他曾担任Xeraya Capital(负责Khazanah Nasional Berhad的生命科学投资)的投资主管(2012年10月以来)。此前,他曾担任Khazanah Nasional公司的生命科学部门(负责Khazanah公司的生命科学投资)的主管(2011年11月以来)。此前,他曾在大波士顿地区兼职咨询,涉及Harvard University、Massachusetts Institute of Technology(MIT)的各种附属各种医疗和清洁技术公司(2009年至2011年)。他也曾担任Salary.com的董事总经理,负责全球开发(从2007年7月到2008年4月)。他曾任职the Yankee Group(全球技术研究和咨询公司)(从2000年9月到2007年3月),最终担任副总裁兼领导团队成员。1997年3月至2000年4月,他曾任职Boston Scientific(财富500强医疗设备制造商)。他任职于一些投资和医疗领域的私人公司的董事会。他持有the University of Southern Maine的学士学位,以及the MIT Sloan School of Management的工商管理硕士学位。
- Aditya Puri served as a member of our board of directors from March 2016 to his resignation in August 2020. Mr. Puri previously served on the board of directors of medical device companies ConforMIS Inc. and ViewRay, Inc. Since October 2012 Mr. Puri has served as an Investment Partner at Xeraya Capital, which, among other mandates, is the exclusive life sciences investments platform for Khazanah Nasional Berhad, the Malaysian government’s strategic investment fund. Mr. Puri received a B.S. from the University of Southern Maine, and an M.B.A from the MIT Sloan School of Management. He has also passed all parts of the U.S. Uniform CPA Examination.
- Mark S. Gold
-
Mark S. Gold,自2004年3月本公司成立之时起,担任董事。1990年以来,他历任University of Florida精神病学的教授、杰出教授、主席,直到2014年6月退休。40多年来,他一直致力于基础科学与临床研究,以及将研究转化为临床阶段的工作。整个职业生涯,他一直是银行、私募股权、风投企业在医疗器械、制药、医疗保健服务行业领域的顾问、高级顾问。1991-1999,他是Somerset Valley Bank、Somerset Valley Financial的创始董事。他从2011年9月起,担任Axogen, Inc.(原LecTec Corporation)的董事。他目前是RiverMend Health的董事长。
Mark S. Gold has served as a member of our board of directors since our founding in March 2004. Dr. Gold was a Professor, Distinguished Professor and Chairman of Psychiatry at the University of Florida from 1990 until his retirement in 2014. Dr. Gold has worked for over 40 years in basic science and clinical research, translating neuroscientific research into clinical practice. He has been a consultant and senior advisor to banks and private equity and venture capital firms on medical devices, pharmaceuticals and health care services throughout his career. He was a Founding Director of the Somerset Valley Bank and Somerset Valley Financial from 1991 to 1999. Dr. Gold has served on the board of directors of Axogen, Inc. formerly LecTec Corporation since September 2011 where he is the chairman of the governance committee and a member of the audit committee. Dr. Gold is also a member of the boards of directors of Magstim Ltd, Wales, UK and RiverMend Health (UK). - Mark S. Gold,自2004年3月本公司成立之时起,担任董事。1990年以来,他历任University of Florida精神病学的教授、杰出教授、主席,直到2014年6月退休。40多年来,他一直致力于基础科学与临床研究,以及将研究转化为临床阶段的工作。整个职业生涯,他一直是银行、私募股权、风投企业在医疗器械、制药、医疗保健服务行业领域的顾问、高级顾问。1991-1999,他是Somerset Valley Bank、Somerset Valley Financial的创始董事。他从2011年9月起,担任Axogen, Inc.(原LecTec Corporation)的董事。他目前是RiverMend Health的董事长。
- Mark S. Gold has served as a member of our board of directors since our founding in March 2004. Dr. Gold was a Professor, Distinguished Professor and Chairman of Psychiatry at the University of Florida from 1990 until his retirement in 2014. Dr. Gold has worked for over 40 years in basic science and clinical research, translating neuroscientific research into clinical practice. He has been a consultant and senior advisor to banks and private equity and venture capital firms on medical devices, pharmaceuticals and health care services throughout his career. He was a Founding Director of the Somerset Valley Bank and Somerset Valley Financial from 1991 to 1999. Dr. Gold has served on the board of directors of Axogen, Inc. formerly LecTec Corporation since September 2011 where he is the chairman of the governance committee and a member of the audit committee. Dr. Gold is also a member of the boards of directors of Magstim Ltd, Wales, UK and RiverMend Health (UK).
- James F. Dempsey
-
James F. Dempsey自2004年3月创立ViewRay起,担任我们的首席科学官。2008年1月起,Dempsey 博士一直是董事会成员。他之前曾在University of Florida放射肿瘤学系任教;2001年7月至2007年7月曾担任助理教授;2007年7月至2008年1月曾担任副教授。Dempsey博士拥有San Jose State University放射学的学士学位和圣路易斯Washington University核化学博士学位。
James F. Dempsey has served as our Chief Scientific Officer since founding ViewRay in March 2004. Dr. Dempsey has been a member of the board of directors since January 2008. He previously served as a faculty member in the University of Florida Department of Radiation Oncology, as Assistant Professor from July 2001 to July 2007 and Associate Professor from July 2007 to January 2008. Dr. Dempsey holds a B.S. in Radiochemistry from San Jose State University and a Ph.D. in Nuclear Chemistry from Washington University in St. Louis. - James F. Dempsey自2004年3月创立ViewRay起,担任我们的首席科学官。2008年1月起,Dempsey 博士一直是董事会成员。他之前曾在University of Florida放射肿瘤学系任教;2001年7月至2007年7月曾担任助理教授;2007年7月至2008年1月曾担任副教授。Dempsey博士拥有San Jose State University放射学的学士学位和圣路易斯Washington University核化学博士学位。
- James F. Dempsey has served as our Chief Scientific Officer since founding ViewRay in March 2004. Dr. Dempsey has been a member of the board of directors since January 2008. He previously served as a faculty member in the University of Florida Department of Radiation Oncology, as Assistant Professor from July 2001 to July 2007 and Associate Professor from July 2007 to January 2008. Dr. Dempsey holds a B.S. in Radiochemistry from San Jose State University and a Ph.D. in Nuclear Chemistry from Washington University in St. Louis.
- Henry A. McKinnell
-
Henry A. McKinnell自2016年4月起担任公司董事。McKinnell现任Moody's Corporation董事长,自2012年4月起开始担任董事长,自1997年10月起担任董事;Accordia Global Health Foundation董事长,自2003年9月起担任董事。McKinnell从2013年2月到2013年10月担任Optimer Pharmaceuticals, Inc.首席执行官;2012年4月到2013年10月担任董事长;2011年1月到2013年10月担任董事。McKinnell还从2010年5月起担任Emmaus Life Sciences, Inc. 董事,2011年5月到2015年9月(离开董事会)担任董事长。他从2008年5月到2011年担任Angiotech Pharmaceuticals, Inc.董事。从1971年到2006年退休期间,McKinnell曾在Pfizer Inc.任职,包括从2001年1月到2006年7月担任Pfizer首席执行官;2001年5月到2006年12月担任董事长。McKinnell持有the University of British Columbia商学位;the Stanford University Graduate School of Business工商管理硕士学位和博士学位。
Henry A. McKinnell has served as a member of our board of directors since April 2016. Dr. McKinnell currently serves as Chairman of the Board of Moody’s Corporation since April 2012 for which he has been a director since October 1997 and Chairman of the Board of the Accordia Global Health Foundation, for which he has been a director since September 2003. Dr. McKinnell served as the Chief Executive Officer of Optimer Pharmaceuticals, Inc. from February 2013 until October 2013 as Chairman of the Board from April 2012 until October 2013 and as a director from January 2011 until October 2013. Dr. McKinnell also served on the Board of Emmaus Life Sciences, Inc. from May 2010 and served as Chairman from May 2011 until leaving the Board in September 2015. He also served as a director of Angiotech Pharmaceuticals, Inc. from May 2008 until 2011. From 1971 until his retirement in 2006 Dr. McKinnell was associated with Pfizer Inc., including serving as Pfizer’s Chief Executive Officer from January 2001 to July 2006 and Chairman of its Board from May 2001 until December 2006. Dr. McKinnell holds a Bachelor’s Degree in business from the University of British Columbia, and M.B.A. and Ph.D. degrees from the Stanford University Graduate School of Business. - Henry A. McKinnell自2016年4月起担任公司董事。McKinnell现任Moody's Corporation董事长,自2012年4月起开始担任董事长,自1997年10月起担任董事;Accordia Global Health Foundation董事长,自2003年9月起担任董事。McKinnell从2013年2月到2013年10月担任Optimer Pharmaceuticals, Inc.首席执行官;2012年4月到2013年10月担任董事长;2011年1月到2013年10月担任董事。McKinnell还从2010年5月起担任Emmaus Life Sciences, Inc. 董事,2011年5月到2015年9月(离开董事会)担任董事长。他从2008年5月到2011年担任Angiotech Pharmaceuticals, Inc.董事。从1971年到2006年退休期间,McKinnell曾在Pfizer Inc.任职,包括从2001年1月到2006年7月担任Pfizer首席执行官;2001年5月到2006年12月担任董事长。McKinnell持有the University of British Columbia商学位;the Stanford University Graduate School of Business工商管理硕士学位和博士学位。
- Henry A. McKinnell has served as a member of our board of directors since April 2016. Dr. McKinnell currently serves as Chairman of the Board of Moody’s Corporation since April 2012 for which he has been a director since October 1997 and Chairman of the Board of the Accordia Global Health Foundation, for which he has been a director since September 2003. Dr. McKinnell served as the Chief Executive Officer of Optimer Pharmaceuticals, Inc. from February 2013 until October 2013 as Chairman of the Board from April 2012 until October 2013 and as a director from January 2011 until October 2013. Dr. McKinnell also served on the Board of Emmaus Life Sciences, Inc. from May 2010 and served as Chairman from May 2011 until leaving the Board in September 2015. He also served as a director of Angiotech Pharmaceuticals, Inc. from May 2008 until 2011. From 1971 until his retirement in 2006 Dr. McKinnell was associated with Pfizer Inc., including serving as Pfizer’s Chief Executive Officer from January 2001 to July 2006 and Chairman of its Board from May 2001 until December 2006. Dr. McKinnell holds a Bachelor’s Degree in business from the University of British Columbia, and M.B.A. and Ph.D. degrees from the Stanford University Graduate School of Business.
- Brian K. Roberts
-
Brian K. Roberts,2015年12月以来,他是我们董事会的成员。他也曾担任Avedro, Inc(私营制药和医疗设备公司)的首席财务官(2015年1月以来),目前担任首席运营官兼首席财务官(2015年12月以来)。任职Avedro公司之前,他曾担任Insulet Corporation(医疗设备公司)的首席财务官(2009年3月以来)。他此前曾担任Jingle Networks的首席财务官(2007年8月至2009年1月),也曾担任Digitas公司的首席财务官(2001年6月至2007年7月)。他也曾担任Idiom Technologies, Inc.、the Monitor Group的财务职务,也曾担任Ernst & Young LLP的审计师。他持有Boston College的会计和财务学士学位。
Brian K. Roberts has served as a member of our board of directors since July 2016. Mr. Roberts currently serves as chief financial officer of Tarveda Therapeutics and serves as a member of the board of directors and audit chairman of ViewRay. From January 2015 to September 2016 Mr. Roberts served as the Chief Operating and Financial Officer of Avedro, a corneal cross-linking science company. From January 2009 through December 2014 he served as Chief Financial Officer for Insulet Corporation, a tubeless insulin pump technology company. From August 2007 to December 2008 Mr. Roberts served as Chief Financial Officer of Jingle Networks, a provider of advertising and technology solutions for voice and mobile business search. Mr. Roberts is currently a member of the board of directors of ViewRay, Inc. and serves as chair of its audit committee. Mr. Roberts received his Bachelor of Science in Accounting and Finance degree from Boston College. - Brian K. Roberts,2015年12月以来,他是我们董事会的成员。他也曾担任Avedro, Inc(私营制药和医疗设备公司)的首席财务官(2015年1月以来),目前担任首席运营官兼首席财务官(2015年12月以来)。任职Avedro公司之前,他曾担任Insulet Corporation(医疗设备公司)的首席财务官(2009年3月以来)。他此前曾担任Jingle Networks的首席财务官(2007年8月至2009年1月),也曾担任Digitas公司的首席财务官(2001年6月至2007年7月)。他也曾担任Idiom Technologies, Inc.、the Monitor Group的财务职务,也曾担任Ernst & Young LLP的审计师。他持有Boston College的会计和财务学士学位。
- Brian K. Roberts has served as a member of our board of directors since July 2016. Mr. Roberts currently serves as chief financial officer of Tarveda Therapeutics and serves as a member of the board of directors and audit chairman of ViewRay. From January 2015 to September 2016 Mr. Roberts served as the Chief Operating and Financial Officer of Avedro, a corneal cross-linking science company. From January 2009 through December 2014 he served as Chief Financial Officer for Insulet Corporation, a tubeless insulin pump technology company. From August 2007 to December 2008 Mr. Roberts served as Chief Financial Officer of Jingle Networks, a provider of advertising and technology solutions for voice and mobile business search. Mr. Roberts is currently a member of the board of directors of ViewRay, Inc. and serves as chair of its audit committee. Mr. Roberts received his Bachelor of Science in Accounting and Finance degree from Boston College.
- Theodore T. Wang
-
TheodoreT.Wang自2017年1月以来一直担任我们的董事会成员。王博士自2015年1月起担任Puissance Capital Management的首席投资官,他是该公司的创始人之一。在此之前,王博士是Goldman,Sachs&Co.“Goldman”的合伙人,他于1996年加入该公司,并担任过许多领导职务,最近担任美国股票交易联席主管、One Delta Trading全球联席主管和Goldman Sachs风险委员会成员。在加入高盛之前,王博士联合创立了Xeotron Corp.,该公司是德克萨斯州一家专门从事DNA生物芯片的公司。王博士拥有明尼苏达大学物理学博士学位,得克萨斯大学奥斯汀分校工商管理硕士学位和中国复旦大学工商管理硕士学位。
Theodore T. Wang,has served as a member of Mariadb Plc Board since the completion of the Business Combination and served as a director of Mangomill plc prior to completion of the Business Combination. Dr. Wang was a co-founder of APHC and served as the chairman of the APHC board of directors and chief executive officer of APHC from January 2021 until the completion of the Business Combination. Dr. Wang is the co-manager of the Sponsor.He was a Partner of Goldman Sachs, where he held many leadership positions over the course of his 18-year tenure. He joined Goldman Sachs in 1996 and was named Managing Director and Head of U.S. Convertibles Trading in 2002. In 2006, he was named a Partner and Co-Head of U.S. Stock Trading, Stock Options Trading, Convertibles Trading, Risk Arbitrage and Franchise Risk Management. In 2009, he became Global Co-COO of One Delta Trading, and in 2012 became the unit's Global Co-Head as well as Co-Head of Equities Trading for the Americas. Upon retiring from Goldman Sachs in 2014, Dr. Wang founded Puissance Capital Management, an asset management firm primarily focusing on investing in innovative healthcare companies in the United States and China. In 2014, he founded Angel Pond Capital LLC, which became an operational broker/dealer firm in 2017 and focuses on advisory services in the life science sector. Dr. Wang serves on the board of one other U.S. public company, Bellerophon Therapeutics, and serves on the board of a privately-held company in China, Angel Pharmaceuticals, which he co-founded. He also serves as an independent director on the Audit Committee of Fiduciary Trust Company, a Division of Franklin Templeton. Dr. Wang previously served as an independent director of Tracon Pharmaceuticals, Inc. until June 2019, of ViewRay, Inc. until July 2019 and of Ekso Bionics Holdings, Inc. until February 2021. Dr. Wang holds a Ph.D in Physics from the University of Minnesota, an MBA from the University of Texas, Austin, and a B.S. from Fudan University in Shanghai, China. He is a trustee of the Dunhuang Foundation, and a member of Committee of 100, an organization of distinguished Chinese Americans with a mission to improve US-China relations. - TheodoreT.Wang自2017年1月以来一直担任我们的董事会成员。王博士自2015年1月起担任Puissance Capital Management的首席投资官,他是该公司的创始人之一。在此之前,王博士是Goldman,Sachs&Co.“Goldman”的合伙人,他于1996年加入该公司,并担任过许多领导职务,最近担任美国股票交易联席主管、One Delta Trading全球联席主管和Goldman Sachs风险委员会成员。在加入高盛之前,王博士联合创立了Xeotron Corp.,该公司是德克萨斯州一家专门从事DNA生物芯片的公司。王博士拥有明尼苏达大学物理学博士学位,得克萨斯大学奥斯汀分校工商管理硕士学位和中国复旦大学工商管理硕士学位。
- Theodore T. Wang,has served as a member of Mariadb Plc Board since the completion of the Business Combination and served as a director of Mangomill plc prior to completion of the Business Combination. Dr. Wang was a co-founder of APHC and served as the chairman of the APHC board of directors and chief executive officer of APHC from January 2021 until the completion of the Business Combination. Dr. Wang is the co-manager of the Sponsor.He was a Partner of Goldman Sachs, where he held many leadership positions over the course of his 18-year tenure. He joined Goldman Sachs in 1996 and was named Managing Director and Head of U.S. Convertibles Trading in 2002. In 2006, he was named a Partner and Co-Head of U.S. Stock Trading, Stock Options Trading, Convertibles Trading, Risk Arbitrage and Franchise Risk Management. In 2009, he became Global Co-COO of One Delta Trading, and in 2012 became the unit's Global Co-Head as well as Co-Head of Equities Trading for the Americas. Upon retiring from Goldman Sachs in 2014, Dr. Wang founded Puissance Capital Management, an asset management firm primarily focusing on investing in innovative healthcare companies in the United States and China. In 2014, he founded Angel Pond Capital LLC, which became an operational broker/dealer firm in 2017 and focuses on advisory services in the life science sector. Dr. Wang serves on the board of one other U.S. public company, Bellerophon Therapeutics, and serves on the board of a privately-held company in China, Angel Pharmaceuticals, which he co-founded. He also serves as an independent director on the Audit Committee of Fiduciary Trust Company, a Division of Franklin Templeton. Dr. Wang previously served as an independent director of Tracon Pharmaceuticals, Inc. until June 2019, of ViewRay, Inc. until July 2019 and of Ekso Bionics Holdings, Inc. until February 2021. Dr. Wang holds a Ph.D in Physics from the University of Minnesota, an MBA from the University of Texas, Austin, and a B.S. from Fudan University in Shanghai, China. He is a trustee of the Dunhuang Foundation, and a member of Committee of 100, an organization of distinguished Chinese Americans with a mission to improve US-China relations.
- Caley Castelein
-
Caley Castelein,医学博士,自2017年3月起担任Aerpio董事会成员。自2006年以来,他一直是Kearny Venture Partners的创始人和董事总经理。他也是KVP Capital的创始人和董事总经理(2013年以来)。他是ViewRay, Boreal和Newbridge Pharmaceuticals的董事。此前,他曾担任Alivecor的董事会成员(2015年4月至2020年3月)。他持有University of California, San Francisco的医学博士学位,以及Harvard University的生物学学士学位。
Caley Castelein, M.D. has served on Aerpio's board of directors since March 2017. Dr. Castelein is the Founder and has been a Managing Director for Kearny Venture Partners since 2006. Dr. Castelein is also the Founder and has been the Managing Director for KVP Capital since 2013. He is a director for ViewRay, Boreal and Newbridge Pharmaceuticals. Previously, Dr. Castelein served on the board of directors of Alivecor from April 2015 to March 2020. Dr. Castelein received his M.D. from University of California, San Francisco and his A.B. in Biology from Harvard University. - Caley Castelein,医学博士,自2017年3月起担任Aerpio董事会成员。自2006年以来,他一直是Kearny Venture Partners的创始人和董事总经理。他也是KVP Capital的创始人和董事总经理(2013年以来)。他是ViewRay, Boreal和Newbridge Pharmaceuticals的董事。此前,他曾担任Alivecor的董事会成员(2015年4月至2020年3月)。他持有University of California, San Francisco的医学博士学位,以及Harvard University的生物学学士学位。
- Caley Castelein, M.D. has served on Aerpio's board of directors since March 2017. Dr. Castelein is the Founder and has been a Managing Director for Kearny Venture Partners since 2006. Dr. Castelein is also the Founder and has been the Managing Director for KVP Capital since 2013. He is a director for ViewRay, Boreal and Newbridge Pharmaceuticals. Previously, Dr. Castelein served on the board of directors of Alivecor from April 2015 to March 2020. Dr. Castelein received his M.D. from University of California, San Francisco and his A.B. in Biology from Harvard University.
- Chris A. Raanes
-
Chris A. Raanes从2002年9月到2011年7月(被提升为执行副总裁,首席运营官)期间担任高级副总裁,首席运营官。从2002年3月至2002年9月他参与个人问题。他从1999年12月到2002年3月担任PerkinElmer Optoelectronics(PerkinElmer, Inc.的业务单元)数码影像的副总裁和总经理,提供广泛的成像产品组合包括用于医疗、军事、商业和工业应用的x射线、紫外线、可见光和红外线探测器。他从1998年12月到1999年12月是Amorphous Silicon(PerkinElmer, Inc.的业务单元,提供用于医疗和工业应用的数码x射线探测器和摄像机)的总经理。他从1992年7月到1998年12月担任多个职位,包括EG&G Reticon(PerkinElmer前身的子公司)的总裁兼总经理。他持有马萨诸塞州,波士顿的麻省理工学院(Massachusetts Institute of Technology)的电机工程学士学位和硕士学位。
Chris A. Raanes served as Senior Vice President and Chief Operating Officer during the period from September 2002 to July 2011 (promoted to Executive Vice President and Chief Operating Officer). From March 2002 to September 2002 he was involved in personal matters. He served as Vice President and General Manager of Digital Imaging from PerkinElmer Optoelectronics (Business Unit, PerkinElmer, Inc.) from December 1999 to March 2002, providing a broad portfolio of imaging products for medical, military, commercial and industrial applications X-ray, ultraviolet, visible and infrared detectors. He was the general manager of Amorphous Silicon (Business Unit, PerkinElmer, Inc., a digital x-ray detector and camera for medical and industrial applications) from December 1998 to December 1999. He held a number of positions from July 1992 to December 1998, including the president and general manager of EG & G Reticon (a subsidiary of PerkinElmer). He holds a bachelor's and master's degree in electrical engineering from the Massachusetts Institute of Technology in Boston, Massachusetts. - Chris A. Raanes从2002年9月到2011年7月(被提升为执行副总裁,首席运营官)期间担任高级副总裁,首席运营官。从2002年3月至2002年9月他参与个人问题。他从1999年12月到2002年3月担任PerkinElmer Optoelectronics(PerkinElmer, Inc.的业务单元)数码影像的副总裁和总经理,提供广泛的成像产品组合包括用于医疗、军事、商业和工业应用的x射线、紫外线、可见光和红外线探测器。他从1998年12月到1999年12月是Amorphous Silicon(PerkinElmer, Inc.的业务单元,提供用于医疗和工业应用的数码x射线探测器和摄像机)的总经理。他从1992年7月到1998年12月担任多个职位,包括EG&G Reticon(PerkinElmer前身的子公司)的总裁兼总经理。他持有马萨诸塞州,波士顿的麻省理工学院(Massachusetts Institute of Technology)的电机工程学士学位和硕士学位。
- Chris A. Raanes served as Senior Vice President and Chief Operating Officer during the period from September 2002 to July 2011 (promoted to Executive Vice President and Chief Operating Officer). From March 2002 to September 2002 he was involved in personal matters. He served as Vice President and General Manager of Digital Imaging from PerkinElmer Optoelectronics (Business Unit, PerkinElmer, Inc.) from December 1999 to March 2002, providing a broad portfolio of imaging products for medical, military, commercial and industrial applications X-ray, ultraviolet, visible and infrared detectors. He was the general manager of Amorphous Silicon (Business Unit, PerkinElmer, Inc., a digital x-ray detector and camera for medical and industrial applications) from December 1998 to December 1999. He held a number of positions from July 1992 to December 1998, including the president and general manager of EG & G Reticon (a subsidiary of PerkinElmer). He holds a bachelor's and master's degree in electrical engineering from the Massachusetts Institute of Technology in Boston, Massachusetts.
- David Bonita
-
David Bonita,2004年6月至2013年6月,Bonita博士在OrbiMed担任其他职务。Bonita博士自2014年1月起担任上市制药公司Tricida, Inc.的董事会成员,自2016年3月起担任心律失常管理公司Acutus Medical Medical Inc,自2016年3月起担任上市肿瘤学公司Ikena Oncology, Inc.,自2016年3月起担任上市肿瘤学公司Prelude Therapeutics,Inc.自2016年7月起担任上市肿瘤学公司,自2019年9月起担任专注于上市癌症的生物技术公司Repare Therapeutics Inc.的董事会成员。Bonita博士此前还曾于2013年4月至2019年4月在上市制药公司Clementia Pharmaceuticals Inc.的董事会任职,此前曾于2013年10月至2017年12月在上市生物制药公司Loxo Oncology, Inc.、2014年4月至2019年6月在上市医疗器械公司SI-BONE, Inc.以及于2008年1月至2018年6月在上市医疗器械公司ViewRay Inc.任职。Bonita博士目前在多家私营公司的董事会任职,此前也曾任职。Bonita博士此前还曾在摩根士丹利和瑞银的医疗保健投资银行集团担任公司融资分析师。他在哈佛医学院进行的基于信号转导研究的同行评审期刊上发表了科学文章。他在哈佛大学获得生物学学士学位,并在哥伦比亚大学获得联合医学博士/工商管理硕士学位。
David Bonita,has served as a member of Board since June 2016. Dr. Bonita is a member at OrbiMed Advisors LLC, an investment firm. Dr. Bonita currently serves on the boards of directors of Acutus Medical, Inc., Ikena Oncology, Inc., Repare Therapeutics Inc., and Third Harmonic Bio, Inc., as well as several private companies. Dr. Bonita also previously served on the boards of directors of IMARA Inc. and Tricida, Inc. Prior to OrbiMed, Dr. Bonita worked as a corporate finance analyst in the healthcare investment banking groups of Morgan Stanley and UBS. He received a B.A. in Biology from Harvard University and a joint M.D./M.B.A. from Columbia University. - David Bonita,2004年6月至2013年6月,Bonita博士在OrbiMed担任其他职务。Bonita博士自2014年1月起担任上市制药公司Tricida, Inc.的董事会成员,自2016年3月起担任心律失常管理公司Acutus Medical Medical Inc,自2016年3月起担任上市肿瘤学公司Ikena Oncology, Inc.,自2016年3月起担任上市肿瘤学公司Prelude Therapeutics,Inc.自2016年7月起担任上市肿瘤学公司,自2019年9月起担任专注于上市癌症的生物技术公司Repare Therapeutics Inc.的董事会成员。Bonita博士此前还曾于2013年4月至2019年4月在上市制药公司Clementia Pharmaceuticals Inc.的董事会任职,此前曾于2013年10月至2017年12月在上市生物制药公司Loxo Oncology, Inc.、2014年4月至2019年6月在上市医疗器械公司SI-BONE, Inc.以及于2008年1月至2018年6月在上市医疗器械公司ViewRay Inc.任职。Bonita博士目前在多家私营公司的董事会任职,此前也曾任职。Bonita博士此前还曾在摩根士丹利和瑞银的医疗保健投资银行集团担任公司融资分析师。他在哈佛医学院进行的基于信号转导研究的同行评审期刊上发表了科学文章。他在哈佛大学获得生物学学士学位,并在哥伦比亚大学获得联合医学博士/工商管理硕士学位。
- David Bonita,has served as a member of Board since June 2016. Dr. Bonita is a member at OrbiMed Advisors LLC, an investment firm. Dr. Bonita currently serves on the boards of directors of Acutus Medical, Inc., Ikena Oncology, Inc., Repare Therapeutics Inc., and Third Harmonic Bio, Inc., as well as several private companies. Dr. Bonita also previously served on the boards of directors of IMARA Inc. and Tricida, Inc. Prior to OrbiMed, Dr. Bonita worked as a corporate finance analyst in the healthcare investment banking groups of Morgan Stanley and UBS. He received a B.A. in Biology from Harvard University and a joint M.D./M.B.A. from Columbia University.
- Josh Bilenker
-
Josh Bilenker, M.D.,他是我们董事会的成员(自2011年12月以来)。2013年7月以来,他担任Loxo Oncology, Inc.的首席执行官、总裁兼董事。2012年1月以来,他担任Aisling Capital的合伙人。从2009年1月到2011年12月,他曾担任 Aisling Capital的负责人。从2004年到2006年,他曾是美国食品和药物管理局(the U.S. Food and Drug Administration)的肿瘤药物产品办公司的卫生官员。在美国食品和药物管理局(the U.S. Food and Drug Administration)的时候,他对 IND-stage和肿瘤生物产品许可进行临床评价。在加入美国食品和药物管理局(the U.S. Food and Drug Administration)之前,他在宾夕法尼亚大学(the University of Pennsylvania)的内科医学和医学肿瘤学进行学习获得了进入董事会的这些证书。他目前是一些私有公司的董事会成员。他也是BioEnterprise Initiative in Cleveland, OH,(私人业务模式、招聘和加速计划增长的医疗保健公司以及进行生物科学技术商业化)董事会成员。 他获得约翰霍普金斯大学医学院(The Johns Hopkins School of Medicine)的医学博士学位。他以优异成绩获得普林斯顿大学(Princeton)的英语学士学位。
Josh Bilenker has served as a member of our board of directors since January 2008. Dr. Bilenker joined Aisling Capital LLC in April 2006 and has served as an Operating Partner since November 2013. He has served as Chief Executive Officer of Loxo Oncology, Inc., an Aisling Capital LLC portfolio company, since July 2013. Previously, Dr. Bilenker served as a Medical Officer in the Office of Oncology Drug Products at the FDA from August 2004 to April 2006. Dr. Bilenker has served on the boards of directors of Loxo Oncology, Inc. since July 2008 T2 Biosystems, Inc. since August 2011 and Roka Bioscience, Inc. since January 2012 as well as on the boards of directors of several private companies. He is also a board member of the NCCN Foundation and BioEnterprise. Dr. Bilenker holds an A.B. in English from Princeton University and an M.D. from the Johns Hopkins School of Medicine. - Josh Bilenker, M.D.,他是我们董事会的成员(自2011年12月以来)。2013年7月以来,他担任Loxo Oncology, Inc.的首席执行官、总裁兼董事。2012年1月以来,他担任Aisling Capital的合伙人。从2009年1月到2011年12月,他曾担任 Aisling Capital的负责人。从2004年到2006年,他曾是美国食品和药物管理局(the U.S. Food and Drug Administration)的肿瘤药物产品办公司的卫生官员。在美国食品和药物管理局(the U.S. Food and Drug Administration)的时候,他对 IND-stage和肿瘤生物产品许可进行临床评价。在加入美国食品和药物管理局(the U.S. Food and Drug Administration)之前,他在宾夕法尼亚大学(the University of Pennsylvania)的内科医学和医学肿瘤学进行学习获得了进入董事会的这些证书。他目前是一些私有公司的董事会成员。他也是BioEnterprise Initiative in Cleveland, OH,(私人业务模式、招聘和加速计划增长的医疗保健公司以及进行生物科学技术商业化)董事会成员。 他获得约翰霍普金斯大学医学院(The Johns Hopkins School of Medicine)的医学博士学位。他以优异成绩获得普林斯顿大学(Princeton)的英语学士学位。
- Josh Bilenker has served as a member of our board of directors since January 2008. Dr. Bilenker joined Aisling Capital LLC in April 2006 and has served as an Operating Partner since November 2013. He has served as Chief Executive Officer of Loxo Oncology, Inc., an Aisling Capital LLC portfolio company, since July 2013. Previously, Dr. Bilenker served as a Medical Officer in the Office of Oncology Drug Products at the FDA from August 2004 to April 2006. Dr. Bilenker has served on the boards of directors of Loxo Oncology, Inc. since July 2008 T2 Biosystems, Inc. since August 2011 and Roka Bioscience, Inc. since January 2012 as well as on the boards of directors of several private companies. He is also a board member of the NCCN Foundation and BioEnterprise. Dr. Bilenker holds an A.B. in English from Princeton University and an M.D. from the Johns Hopkins School of Medicine.
高管简历
中英对照 |  中文 |  英文- James F. Dempsey
James F. Dempsey自2004年3月创立ViewRay起,担任我们的首席科学官。2008年1月起,Dempsey 博士一直是董事会成员。他之前曾在University of Florida放射肿瘤学系任教;2001年7月至2007年7月曾担任助理教授;2007年7月至2008年1月曾担任副教授。Dempsey博士拥有San Jose State University放射学的学士学位和圣路易斯Washington University核化学博士学位。
James F. Dempsey has served as our Chief Scientific Officer since founding ViewRay in March 2004. Dr. Dempsey has been a member of the board of directors since January 2008. He previously served as a faculty member in the University of Florida Department of Radiation Oncology, as Assistant Professor from July 2001 to July 2007 and Associate Professor from July 2007 to January 2008. Dr. Dempsey holds a B.S. in Radiochemistry from San Jose State University and a Ph.D. in Nuclear Chemistry from Washington University in St. Louis.- James F. Dempsey自2004年3月创立ViewRay起,担任我们的首席科学官。2008年1月起,Dempsey 博士一直是董事会成员。他之前曾在University of Florida放射肿瘤学系任教;2001年7月至2007年7月曾担任助理教授;2007年7月至2008年1月曾担任副教授。Dempsey博士拥有San Jose State University放射学的学士学位和圣路易斯Washington University核化学博士学位。
- James F. Dempsey has served as our Chief Scientific Officer since founding ViewRay in March 2004. Dr. Dempsey has been a member of the board of directors since January 2008. He previously served as a faculty member in the University of Florida Department of Radiation Oncology, as Assistant Professor from July 2001 to July 2007 and Associate Professor from July 2007 to January 2008. Dr. Dempsey holds a B.S. in Radiochemistry from San Jose State University and a Ph.D. in Nuclear Chemistry from Washington University in St. Louis.
- Douglas H. Keare
Douglas H. Keare,2015年4月以来,他一直担任我们的首席营运官。他拥有20年以上的技术和医疗设备管理经验。加入ViewRay公司之前,他曾做咨询工作,并建议一个创业公司(2014年1月至2015年4月)。他曾创立并担任RallyOn, Inc.(一家软件公司,专注于企业健康和健康)的首席执行官(从2008年10月到2013年12月)。此前,他曾担任Accuray Inc.的客户和技术支持副总裁(从2002年12月到2007年1月)。他也曾担任Pricing Dynamics的总裁兼首席营运官(从2000年7月到2002年7月)。他曾担任ADAC Laboratories的一些职务,涉及客户支持、操作和质量(从1992年10月到1999年3月)。作为质量副总裁,他曾领导ADAC于1996年成功赢得the Malcolm Baldridge National Quality Award。他持有Dartmouth College的经济学学士学位,以及Stanford University Graduate School of Business的工商管理硕士学位。
Douglas H. Keare has served as our Chief Operating Officer since April 2015. Before joining ViewRay, Mr. Keare was doing consulting work with and/or advising a number of startup companies from January 2014 to April 2015. He founded and served as CEO of RallyOn, Inc., a software company focused on corporate health and wellness, from October 2008 to December 2013. Prior to that, Mr. Keare served as Vice President of Customer and Technical Support at Accuray Inc. from December 2002 to January 2007. Mr. Keare also served as the President and Chief Operating Officer for Pricing Dynamics from July 2000 to July 2002. He held several positions at ADAC Laboratories in Customer Support, Operations and Quality from October 1992 to March 1999. As Vice President of Quality, he led ADAC’s successful effort to win the Malcolm Baldridge National Quality Award in 1996. Mr. Keare received a B.A. in Economics from Dartmouth College and an M.B.A. from Stanford University’s Graduate School of Business.- Douglas H. Keare,2015年4月以来,他一直担任我们的首席营运官。他拥有20年以上的技术和医疗设备管理经验。加入ViewRay公司之前,他曾做咨询工作,并建议一个创业公司(2014年1月至2015年4月)。他曾创立并担任RallyOn, Inc.(一家软件公司,专注于企业健康和健康)的首席执行官(从2008年10月到2013年12月)。此前,他曾担任Accuray Inc.的客户和技术支持副总裁(从2002年12月到2007年1月)。他也曾担任Pricing Dynamics的总裁兼首席营运官(从2000年7月到2002年7月)。他曾担任ADAC Laboratories的一些职务,涉及客户支持、操作和质量(从1992年10月到1999年3月)。作为质量副总裁,他曾领导ADAC于1996年成功赢得the Malcolm Baldridge National Quality Award。他持有Dartmouth College的经济学学士学位,以及Stanford University Graduate School of Business的工商管理硕士学位。
- Douglas H. Keare has served as our Chief Operating Officer since April 2015. Before joining ViewRay, Mr. Keare was doing consulting work with and/or advising a number of startup companies from January 2014 to April 2015. He founded and served as CEO of RallyOn, Inc., a software company focused on corporate health and wellness, from October 2008 to December 2013. Prior to that, Mr. Keare served as Vice President of Customer and Technical Support at Accuray Inc. from December 2002 to January 2007. Mr. Keare also served as the President and Chief Operating Officer for Pricing Dynamics from July 2000 to July 2002. He held several positions at ADAC Laboratories in Customer Support, Operations and Quality from October 1992 to March 1999. As Vice President of Quality, he led ADAC’s successful effort to win the Malcolm Baldridge National Quality Award in 1996. Mr. Keare received a B.A. in Economics from Dartmouth College and an M.B.A. from Stanford University’s Graduate School of Business.
- Chris A. Raanes
Chris A. Raanes从2002年9月到2011年7月(被提升为执行副总裁,首席运营官)期间担任高级副总裁,首席运营官。从2002年3月至2002年9月他参与个人问题。他从1999年12月到2002年3月担任PerkinElmer Optoelectronics(PerkinElmer, Inc.的业务单元)数码影像的副总裁和总经理,提供广泛的成像产品组合包括用于医疗、军事、商业和工业应用的x射线、紫外线、可见光和红外线探测器。他从1998年12月到1999年12月是Amorphous Silicon(PerkinElmer, Inc.的业务单元,提供用于医疗和工业应用的数码x射线探测器和摄像机)的总经理。他从1992年7月到1998年12月担任多个职位,包括EG&G Reticon(PerkinElmer前身的子公司)的总裁兼总经理。他持有马萨诸塞州,波士顿的麻省理工学院(Massachusetts Institute of Technology)的电机工程学士学位和硕士学位。
Chris A. Raanes served as Senior Vice President and Chief Operating Officer during the period from September 2002 to July 2011 (promoted to Executive Vice President and Chief Operating Officer). From March 2002 to September 2002 he was involved in personal matters. He served as Vice President and General Manager of Digital Imaging from PerkinElmer Optoelectronics (Business Unit, PerkinElmer, Inc.) from December 1999 to March 2002, providing a broad portfolio of imaging products for medical, military, commercial and industrial applications X-ray, ultraviolet, visible and infrared detectors. He was the general manager of Amorphous Silicon (Business Unit, PerkinElmer, Inc., a digital x-ray detector and camera for medical and industrial applications) from December 1998 to December 1999. He held a number of positions from July 1992 to December 1998, including the president and general manager of EG & G Reticon (a subsidiary of PerkinElmer). He holds a bachelor's and master's degree in electrical engineering from the Massachusetts Institute of Technology in Boston, Massachusetts.- Chris A. Raanes从2002年9月到2011年7月(被提升为执行副总裁,首席运营官)期间担任高级副总裁,首席运营官。从2002年3月至2002年9月他参与个人问题。他从1999年12月到2002年3月担任PerkinElmer Optoelectronics(PerkinElmer, Inc.的业务单元)数码影像的副总裁和总经理,提供广泛的成像产品组合包括用于医疗、军事、商业和工业应用的x射线、紫外线、可见光和红外线探测器。他从1998年12月到1999年12月是Amorphous Silicon(PerkinElmer, Inc.的业务单元,提供用于医疗和工业应用的数码x射线探测器和摄像机)的总经理。他从1992年7月到1998年12月担任多个职位,包括EG&G Reticon(PerkinElmer前身的子公司)的总裁兼总经理。他持有马萨诸塞州,波士顿的麻省理工学院(Massachusetts Institute of Technology)的电机工程学士学位和硕士学位。
- Chris A. Raanes served as Senior Vice President and Chief Operating Officer during the period from September 2002 to July 2011 (promoted to Executive Vice President and Chief Operating Officer). From March 2002 to September 2002 he was involved in personal matters. He served as Vice President and General Manager of Digital Imaging from PerkinElmer Optoelectronics (Business Unit, PerkinElmer, Inc.) from December 1999 to March 2002, providing a broad portfolio of imaging products for medical, military, commercial and industrial applications X-ray, ultraviolet, visible and infrared detectors. He was the general manager of Amorphous Silicon (Business Unit, PerkinElmer, Inc., a digital x-ray detector and camera for medical and industrial applications) from December 1998 to December 1999. He held a number of positions from July 1992 to December 1998, including the president and general manager of EG & G Reticon (a subsidiary of PerkinElmer). He holds a bachelor's and master's degree in electrical engineering from the Massachusetts Institute of Technology in Boston, Massachusetts.
- Ajay Bansal
Ajay Bansal,2010年5月以来,他一直担任我们的首席财务官。从2009年1月到2010年1月,他担任Lexicon Pharmaceuticals公司(一个生物制药公司)的首席财务官,以及商业开发执行副总裁。从2007年12月到2008年10月,他曾担任Tercica公司(the Ipsen Group于2008年10月收购的生物制药公司)的首席财务官兼财务执行副总裁。他也曾担任Tercica公司的首席财务官,以及高级财务副总裁(从2006年3月到2007年12月)。从2003年2月到2006年1月,他担任Nektar Therapeutics公司(一个生物制药公司)的财务行政副总裁,以及首席财务官。从2002年7月到2003年2月,他曾担任Capital One Financial公司(一家银行控股公司)的运营分析董事。从1998年8月到2002年6月,他曾任职Mehta Partners公司(财务咨询公司),在那里他于2000年1月被任命为合伙人。加入Mehta Partners公司之前,他曾担任Novartis公司(制药公司)的管理职务,以及Arthur D. Little公司、McKinsey & Company公司、ZS Associates公司的咨询职务10年以上。他持有the Indian Institute of Technology Delhi的机械工程学学士学位,以及美国东北大学 (Northeastern University)的运营管理硕士学位和工商管理硕士学位。
Ajay Bansal has served as our Chief Financial Officer since May 2010. From June 2009 to January 2010 Mr. Bansal served as Chief Financial Officer and Executive Vice President of Business Development at Lexicon Pharmaceuticals, Inc., a biopharmaceutical company. From December 2007 to October 2008 Mr. Bansal served as Chief Financial Officer and Executive Vice President of Finance of Tercica, Inc., a biopharmaceutical company acquired by the Ipsen Group in October 2008. He also served as Chief Financial Officer and Senior Vice President of Finance of Tercica from March 2006 until December 2007. From February 2003 to January 2006 Mr. Bansal served as Vice Present of Finance and Administration and Chief Financial Officer of Nektar Therapeutics, a biopharmaceutical company. From July 2002 to February 2003 Mr. Bansal served as Director of Operations Analysis at Capital One Financial, a bank holding company. From August 1998 to June 2002 Mr. Bansal was at Mehta Partners LLC, a financial advisory firm, where he was named partner in January 2000. Prior to joining Mehta Partners, Mr. Bansal spent more than ten years in manment roles at Novartis, a pharmaceuticals company, and in consulting at Arthur D. Little, Inc., McKinsey & Company, Inc. and ZS Associates. Mr. Bansal received a B.S. in Mechanical Engineering from the Indian Institute of Technology Delhi and an M.S. in Operations Management and an M.B.A. from Northwestern University.- Ajay Bansal,2010年5月以来,他一直担任我们的首席财务官。从2009年1月到2010年1月,他担任Lexicon Pharmaceuticals公司(一个生物制药公司)的首席财务官,以及商业开发执行副总裁。从2007年12月到2008年10月,他曾担任Tercica公司(the Ipsen Group于2008年10月收购的生物制药公司)的首席财务官兼财务执行副总裁。他也曾担任Tercica公司的首席财务官,以及高级财务副总裁(从2006年3月到2007年12月)。从2003年2月到2006年1月,他担任Nektar Therapeutics公司(一个生物制药公司)的财务行政副总裁,以及首席财务官。从2002年7月到2003年2月,他曾担任Capital One Financial公司(一家银行控股公司)的运营分析董事。从1998年8月到2002年6月,他曾任职Mehta Partners公司(财务咨询公司),在那里他于2000年1月被任命为合伙人。加入Mehta Partners公司之前,他曾担任Novartis公司(制药公司)的管理职务,以及Arthur D. Little公司、McKinsey & Company公司、ZS Associates公司的咨询职务10年以上。他持有the Indian Institute of Technology Delhi的机械工程学学士学位,以及美国东北大学 (Northeastern University)的运营管理硕士学位和工商管理硕士学位。
- Ajay Bansal has served as our Chief Financial Officer since May 2010. From June 2009 to January 2010 Mr. Bansal served as Chief Financial Officer and Executive Vice President of Business Development at Lexicon Pharmaceuticals, Inc., a biopharmaceutical company. From December 2007 to October 2008 Mr. Bansal served as Chief Financial Officer and Executive Vice President of Finance of Tercica, Inc., a biopharmaceutical company acquired by the Ipsen Group in October 2008. He also served as Chief Financial Officer and Senior Vice President of Finance of Tercica from March 2006 until December 2007. From February 2003 to January 2006 Mr. Bansal served as Vice Present of Finance and Administration and Chief Financial Officer of Nektar Therapeutics, a biopharmaceutical company. From July 2002 to February 2003 Mr. Bansal served as Director of Operations Analysis at Capital One Financial, a bank holding company. From August 1998 to June 2002 Mr. Bansal was at Mehta Partners LLC, a financial advisory firm, where he was named partner in January 2000. Prior to joining Mehta Partners, Mr. Bansal spent more than ten years in manment roles at Novartis, a pharmaceuticals company, and in consulting at Arthur D. Little, Inc., McKinsey & Company, Inc. and ZS Associates. Mr. Bansal received a B.S. in Mechanical Engineering from the Indian Institute of Technology Delhi and an M.S. in Operations Management and an M.B.A. from Northwestern University.
- Ajay Bansal
- 暂无中文简介
Ajay Bansal has served as our Chief Financial Officer since June 2016. Mr. Bansal previously served as the Chief Financial Officer of Onconova Therapeutics, Inc. “Onconova” from March 2013 to February 2016. He also served as a member of the Board of Directors of Onconova from March 2013 until immediately prior to the listing of Onconova’s common stock on the NASDAQ Global Market in July 2013. From May 2010 to March 2013 Mr. Bansal served as Chief Financial Officer of Complete Genomics Incorporated, a life sciences company. From June 2009 to January 2010 Mr. Bansal served as Chief Financial Officer of Lexicon Pharmaceuticals, Inc., a biopharmaceutical company. From March 2006 to October 2008 Mr. Bansal served as Chief Financial Officer of Tercica, Inc., a biopharmaceutical company. From February 2003 to January 2006 Mr. Bansal served as Chief Financial Officer of Nektar Therapeutics, also a biopharmaceutical company. Prior to joining Nektar Therapeutics, Mr. Bansal spent more than 15 years as a management consultant at Arthur D. Little, Inc., McKinsey & Company, Inc. and ZS Associates, Inc., in management roles at Novartis Corporation, a pharmaceuticals company, at Mehta Partners, a financial advisory firm, and at Capital One, a bank holding company. Mr. Bansal received a B.S. in Mechanical Engineering from the Indian Institute of Technology (Delhi) and an M.S. in Operations Research and an M.B.A. from Northwestern University. - 暂无中文简介
- Ajay Bansal has served as our Chief Financial Officer since June 2016. Mr. Bansal previously served as the Chief Financial Officer of Onconova Therapeutics, Inc. “Onconova” from March 2013 to February 2016. He also served as a member of the Board of Directors of Onconova from March 2013 until immediately prior to the listing of Onconova’s common stock on the NASDAQ Global Market in July 2013. From May 2010 to March 2013 Mr. Bansal served as Chief Financial Officer of Complete Genomics Incorporated, a life sciences company. From June 2009 to January 2010 Mr. Bansal served as Chief Financial Officer of Lexicon Pharmaceuticals, Inc., a biopharmaceutical company. From March 2006 to October 2008 Mr. Bansal served as Chief Financial Officer of Tercica, Inc., a biopharmaceutical company. From February 2003 to January 2006 Mr. Bansal served as Chief Financial Officer of Nektar Therapeutics, also a biopharmaceutical company. Prior to joining Nektar Therapeutics, Mr. Bansal spent more than 15 years as a management consultant at Arthur D. Little, Inc., McKinsey & Company, Inc. and ZS Associates, Inc., in management roles at Novartis Corporation, a pharmaceuticals company, at Mehta Partners, a financial advisory firm, and at Capital One, a bank holding company. Mr. Bansal received a B.S. in Mechanical Engineering from the Indian Institute of Technology (Delhi) and an M.S. in Operations Research and an M.B.A. from Northwestern University.